Ticagrelor: the first novel reversible P2Y₁₂ inhibitor

Bibliography

• Anderson JL, Adams CD, Antman EM, ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction- executive summary. J Am Coll Cardiol 2007;50:652-726
   Web of Science ®Google Scholar
• Dib C, Hanna EB, Abu-Fadel MS. A new era for antiplatelet therapy in patients with acute coronary syndrome. Am J med Sci 2010;340:407-11
   Google Scholar
• Brar SS, ten Berg J, Marcucci R, Impact of platelet reactivity on clinical outcomes after percutaneous coronary interventions: a collaborative metanalysis of individual participant data. J Am Coll Cardiol 2011;58:1945-54
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Ancerenaz V, Daali Y, Fontana P, Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel esponse variability. Curr Drug Metab 2010;11(8):667-77
   Google Scholar
• Bonello L, Pansieri M, Mancini J, High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-73
   PubMed Web of Science ®Google Scholar
• Libby P. Current concepts of the pathogenesis of acute coronary syndromes. Circulation 2001;104:365-72
   PubMed Web of Science ®Google Scholar
• Brilinta label in USA. Available from: www1.astrazeneca-us.com/pi/brilinta.pdf
   Google Scholar
• Brilique EU label 2010. Available from: http://ec.europa.eu/health/documents/community-register/2010/2010120390969/anx_90969_en.pdf
   Google Scholar
• Iyu D, Glenn JR, White AE, Mode of action of P2Y12 antagonists as inhibitors of platelet function. Thromb Haemost 2011;105(1):187-92
   Google Scholar
• Teng R, Butler K. Pharmacokinetics, pharmacodynamics, safety of single ascending doses of ticagrelor, a reversible binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010;66(5):487-96
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010;70(1):65-77
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Randomized double-blind assessment of the ONSET and OFFset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/OffSET study. Circulation 2009;120(25):2577-85
   PubMed Web of Science ®Google Scholar
• van Giezen JJJ, Berntsson P, Zachrisson H, Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009;124(5):565-71
   Google Scholar
• Wang K, Zhou X, Huang Y, Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recannalization with recovery of myocardial perfusion in a canine coronary thrombosis mode. Thromb Haemost 2010;104(3):609-17
   Google Scholar
• Bjorkman JA, Kirk I, van Giezen JJ. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Circulation 2007;116(16 Suppl):11-28
   Google Scholar
• Serebruany VL. Adenosine release: a potential explanation for benefits of ticagrelor in the Platelet inhibition and clinical outcomes trial? Am Heart J 2011;161:1-4
   PubMed Web of Science ®Google Scholar
• Hogberg C, Svensson H, Gustafsson R. The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol 2010;142(2):187-92
   PubMed Web of Science ®Google Scholar
• Deeks ED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs 2011;71(7):909-33
   Google Scholar
• Grzesk G, Kozinski M, Navarese EP, Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-innduced vascualar smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res 2012;130(1):65-9
   Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA, For the DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-STsegment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51
   PubMedGoogle Scholar
• Gurbel PA, Bliden KP, Butler K, Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies. The RESPOND study. Circulation 2010;121:1188-99
   PubMed Web of Science ®Google Scholar
• Bliden KP, Tantry US, Storey RF, The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011;162:160-5
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Schneider DJ. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. J Am Coll Cardiol 2011;57:685-7
   PubMedGoogle Scholar
• Mahaffey KW, Wojdyla DM, Crroll K, Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2011;124(5):544-54
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet 2010;375(9711):283-93
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Harrington RA, Ticagrelor Versus Clopidogrel in patients with ST-Elevation Acute Coronary Syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation 2010;122L:2131-41
   Google Scholar
• Wijeyeratne YD, Joshi R, Heptinstall S. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes. Expert Rev Clin Pharmacol 2012;5(3):257-69
   PubMed Web of Science ®Google Scholar
• Held C, Asenblad N, Bassand JP, Ticagrelor Versus Clopidogrel in patients with acute coronary syndromes undergoing coronary bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol 2011;57(6):672-84
   PubMed Web of Science ®Google Scholar
• Varenhorst C, Alstrom U, Scirica BM, Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012;60(17):1623-30
   Google Scholar
• James SK, Roe MT, Cannon CP, Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibitionand patient Outcomes (PLATO) trial. BMJ 2011;342:d3527
   PubMed Web of Science ®Google Scholar
• Wallentin L, James SK, Storey RF, Effect of CYP2C19 and ABCB1 Single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376(9749):1320-8
   PubMed Web of Science ®Google Scholar
• James SK, Budaj A, Aylward P, Ticagrelor versus clopidogrel in patients with acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010;122(11):1056-67
   PubMed Web of Science ®Google Scholar
• James SK, Angiolillo DJ, Cornel JH, Ticagrelor versus clopidogrel in patients with acute coronary syndromes and Diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Eur Heart J 2010;31(24):3006-16
   PubMed Web of Science ®Google Scholar
• Husted S, James S, Becker RC, Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Cardiovasc Qual Outcomes 2012;5:680-8
   PubMed Web of Science ®Google Scholar
• James SK, Storey RF, Khurmi NS, Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012;125:2914-21
   PubMed Web of Science ®Google Scholar
• Burki NK, Dale WJ, Lee L-Y. Intravenous adenosine and dyspnoea in humans. J appl Physiol 2005;98:180-5
   PubMed Web of Science ®Google Scholar
• Dinicolantonio JJ, Serebruany VL. Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? Clin Cardiol 2012;35(11):647-8
   Google Scholar
• Hamm CW, Bassand JP, Agewall S, ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32(23):2999-3054
   PubMed Web of Science ®Google Scholar
• 2012 Writing Committee Members. Jneid H, Anderson JL, Wright RS, 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non− ST-Elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a Report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2012;126:875-910
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33(20):2569-619
   PubMed Web of Science ®Google Scholar